Seeking Alpha

stock-PR.com's  Instablog

stock-PR.com
Send Message
View stock-PR.com's Instablogs on:
  • Green Mountain Coffee Roasters (GMCR) Q4 FY2012 Financial Results, Revenue And Earnings Growth

    stockpr_logo-site

    FREE Daily Stock Alerts From Stock-PR.com

    chartstockalert

    http://static.cdn-seekingalpha.com/uploads/2012/11/28/saupload_gmcr.jpg GMCR, Green Mountain Coffee Roasters, Inc.

    ** For the fourth quarter fiscal 2012, GMCR posted net sales of $946.7 million, a 33% increase year over year, and GAAP net income of $91.9 million, a 22% increase compared to the same period the prior year.

    According to its outlook for its first quarter of fiscal year 2013, GMCR expects that its total net sales growth in the range of 14% to 18% over the first quarter of fiscal year 2012.

    http://static.cdn-seekingalpha.com/uploads/2012/11/28/saupload_gmcr_chart.jpg

    As a leader in specialty coffee and coffee makers, GMCR is recognized for its award-winning coffees, innovative Keurig® Single Cup brewing technology, and socially responsible business practices.

    More about GMCR at www.GMCR.com.

    **************************************************************

    Read Full Disclaimer at http://stock-pr.com/disclaimer

    stock-pr.com/22049/stock-alerts/green-mo.../

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Nov 28 11:56 AM | Link | Comment!
  • ACADIA Pharmaceuticals (ACAD) Antipsychotic For Parkinson's Disease Succeeds In Trial

    stockpr_logo-site

    FREE Daily Stock Alerts From Stock-PR.com

    chartstockalert

    http://static.cdn-seekingalpha.com/uploads/2012/11/27/saupload_acad.jpg ACAD, ACADIA Pharmaceuticals Inc.

    ** ACAD reported successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinson’s disease psychosis (NYSEARCA:PDP).

    Pimavanserin is ACAD’s proprietary, non-dopaminergic product candidate that selectively blocks serotonin 5-HT2A receptors.

    Pimavanserin met the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson’s Disease Rating Scale, or UPDRS. These results were further supported by a highly significant improvement in the secondary efficacy measure, the Clinical Global Impression Improvement, or CGI-I, scale (p=0.001).

    In addition, clinical benefits were observed in all exploratory efficacy measures with significant improvements in nighttime sleep, daytime wakefulness and caregiver burden. Consistent with previous studies, pimavanserin was safe and well tolerated in this Phase III trial.

    According to the National Parkinson’s Foundation, about one million people in the United States and from four to six million people worldwide suffer from Parkinson’s disease. Parkinson’s disease psychosis, or PDP, is a debilitating disorder that develops in up to 60 percent of patients with Parkinson’s disease.

    http://static.cdn-seekingalpha.com/uploads/2012/11/27/saupload_acad_chart.png

    ACAD is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders.

    More about ACAD at www.acadia-pharm.com

    **************************************************************

    Read Full Disclaimer at http://stock-pr.com/disclaimer

    stock-pr.com/22048/stock-alerts/acadia-p.../

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Nov 27 2:13 PM | Link | Comment!
  • Galectin Therapeutics (GALT) Gets US Patent "Galactose-Prolonged Polysaccharides In A Formulation For Antifibrotic Therapies"

    stockpr_logo-site

    FREE Daily Stock Alerts From Stock-PR.com

    chartstockalert

    http://static.cdn-seekingalpha.com/uploads/2012/11/26/saupload_galt.jpg GALT, Galectin Therapeutics, Inc.

    ** GALT reported that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies”.

    The patent covers key methods of derivation and use for the Company’s galactomannan-based carbohydrate galectin inhibitor compounds, for use in patients with chronic liver disease associated with the development of fibrosis, established liver fibrosis or end-stage scarring, or cirrhosis.

    Fibrotic disease of the liver is highly prevalent in the population because all chronic liver diseases, including viral hepatitis, fatty liver and alcohol abuse, result in fibrosis of the liver for which there are no currently approved pharmaceutical therapies.

    http://static.cdn-seekingalpha.com/uploads/2012/11/26/saupload_galt_chart.png

    GALT is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.

    More about GALT at www.galectintherapeutics.com.

    **************************************************************

    Read Full Disclaimer at http://stock-pr.com/disclaimer

    stock-pr.com/22047/stock-alerts/galectin.../

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Nov 26 2:13 PM | Link | Comment!
Full index of posts »
Latest Followers
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.